Objective To explore the clinical effect of Docetaxel combined with Apatinib in the second-line treatment of advanced gastric cancer.Methods A total of 60 patients with second-line treatment advanced gastric cancer who came to our hospital from July 2018 to August 2019 were selected as the research objects,and they were divided into reference group(30 cases)and experimental group(30 cases)by random number tablemethod.The patients in the reference group used Docetaxel.In the experimental group,patientswere treated with Docetaxel combined with Apatinib.The disease remission,adverse reactions,and total treatment satisfaction were compared between the two groups.The nutritional status scores before and after treatment,quality of life scores (including functional items,symptom items)and serum tumor markers (sugar carbohydrate antigen [CA19-9],carbohydrate antigen sugar chain antigen 72-4[CA72-4])measured valueswere observed and recorded in the two groups.Results The objective remission rate of the experimental group was higher than that of the reference group,the difference was statistically significant(P＜0.05).The total incidence of adverse reaction of the experimental group was lower than that of the reference group,the difference was statistically significant(P＜0.05).The total treatment satisfaction rate of the experimental group was higher than that of the reference group,the difference was statistically significant(P＜0.05).There were no significant differences between the two groups in the nutritional status scores before treatment(P＞0.05).After treatment,the nutritional status score of the experimental group was higher than that of the reference group,and the difference was statistically significant(P＜0.05).Therewere no significant differences between the two groups in functional item scores and symptom item scores before treatment(P＞0.05).After treatment,the score of functional items in the experimental group was higher than that in the reference group,the score of symptom item was lower than that in the reference group,and the differences were statistically significant(P＜0.05).There were no significant differences between the two groups in the indexesmeasured values of CA9-9 and CA72-4before treatment(P＞0.05).After treatment,the indexesmeasured values of CA19-9 and CA72-4in the experimental group were lower than those in the reference group,and the differenceswere statistically significant(P＜0.05).Conclusion The combination of Docetaxel and Apatinib in the second-line treatment of patientswith advanced gastric cancer has a good clinical effect and isworth promoting.